Sonoma制药公司将通过虚拟网播出席2025年9月30日的Lytham伙伴2025年秋季投资者会议。 Sonoma Pharmaceuticals will present at the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, via virtual webcast.

Sonoma制药公司(纳斯达克:SNOA)将于2025年9月30日下午2:00通过虚拟网播出席Lytham伙伴2025年秋季投资者会议。 Sonoma Pharmaceuticals (Nasdaq: SNOA) will present at the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, via a virtual webcast at 2:00 p.m. ET,然后是一对一的投资者会议。 ET, followed by one-on-one investor meetings. 该公司总部设在科罗拉多州Boulder,开发了用于创伤护理、皮肤科、眼科护理、心脏科、动物健康和消毒的具有专利的微氯乙烯稳定低氯酸(HOCl)产品。 The company, based in Boulder, Colorado, develops patented Microcyn® stabilized hypochlorous acid (HOCl) products used in wound care, dermatology, eye care, podiatry, animal health, and disinfection. 其产品在临床上显示会减少痒痒、疼痛和刺激,不会损害健康组织,并通过直接销售和合作伙伴在55个以上国家销售。 Its products are clinically shown to reduce itch, pain, and irritation without harming healthy tissue and are sold in over 55 countries through direct sales and partners. 制造业在墨西哥瓜达拉哈拉,欧洲在荷兰Roermond经营。 Manufacturing is in Guadalajara, Mexico, with European operations in Roermond, Netherlands. 该公司指出,前瞻性声明涉及监管变化、临床结果、市场接受和专利保护等风险,并否认除法律规定外任何更新义务。 The company notes forward-looking statements involve risks such as regulatory changes, clinical outcomes, market acceptance, and patent protection, and disclaims any obligation to update them except as required by law.